Safety of vedolizumab in the treatment of pregnant women with inflammatory bowel disease: a targeted literature review.

ABSTRACT:

Background

Crohn's disease (CD) and ulcerative colitis (UC) commonly affect women in their childbearing years. Vedolizumab (VDZ) is approved for treatment of moderate-to-severe CD and UC, but there is a knowledge gap regarding its use during pregnancy. This targeted literature review describes available evidence on safety of VDZ in pregnant patients in order to offer physicians a detailed and balanced view on persistent data during their decision-making process for an individualized treatment concept.

Methods

The search included literature from the MEDLINE database and abstracts of five gastroenterological conferences published until November 2019. Publications were included if pregnancy outcomes in women receiving VDZ or neonatal outcomes in newborns of women previously exp

SUBMITTER: Terjung B 

PROVIDER: S-EPMC7580131 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature